Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy.
about
Non-steroidal anti-inflammatory agents to induce regression and prevent the progression of cervical intraepithelial neoplasiaEGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target.Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group studyPhase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group studyEGFR and HER2 expression in primary cervical cancers and corresponding lymph node metastases: implications for targeted radiotherapy.Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer.Correlation between tumor volume response to radiotherapy and expression of biological markers in patients with cervical squamous cell carcinoma.Gallic acid reduces cell viability, proliferation, invasion and angiogenesis in human cervical cancer cells.Prognostic role of vascular endothelial growth factor in cervical cancer: a meta-analysis.Importance of adrenergic pathways in women's cancersPhase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study.Anti-EGFR-Conjugated Hollow Gold Nanospheres Enhance Radiocytotoxic Targeting of Cervical Cancer at Megavoltage Radiation EnergiesPrognostic Impact of Epidermal Growth Factor Receptor Overexpression in Patients with Cervical Cancer: A Meta-Analysis.The relevance of molecular biomarkers in cervical cancer patients treated with radiotherapy.Epithelial-mesenchymal transition, proliferation, and angiogenesis in locally advanced cervical cancer treated with chemoradiotherapy.Can ABCF2 protein expression predict the prognosis of uterine cancer?Clinical biomarkers of angiogenesis inhibition.Inflammation and cancer: how friendly is the relationship for cancer patients?Emerging biological treatments for uterine cervical carcinoma.Epidermal growth factor receptor as a biomarker for cervical cancer.Next-generation treatment strategies for human papillomavirus-related head and neck squamous cell carcinoma: where do we go?Cytokines as potential tumour markers.Prognostic significance of human papillomavirus (HPV) status and expression of selected markers (HER2/neu, EGFR, VEGF, CD34, p63, p53 and Ki67/MIB-1) on outcome after (chemo-) radiotherapy in patients with squamous cell carcinoma of uterine cervix.Epidermal growth factor receptor-targeted therapy.Inhibition of Epidermal Growth Factor Receptor and PI3K/Akt Signaling Suppresses Cell Proliferation and Survival through Regulation of Stat3 Activation in Human Cutaneous Squamous Cell Carcinoma.Deregulation of the miRNAs expression in cervical cancer: human papillomavirus implications.High-risk human papillomavirus load and biomarkers in cervical intraepithelial neoplasia and cancer.Prognostic implications of tumor volume response and COX-2 expression change during radiotherapy in cervical cancer patients.ADAM17 is associated with EMMPRIN and predicts poor prognosis in patients with uterine cervical carcinoma.Prognostic significance of cyclooxygenase-2 in cervical cancer: a meta-analysis.let-7i-5p, miR-181a-2-3p and EGF/PI3K/SOX2 axis coordinate to maintain cancer stem cell population in cervical cancer.
P2860
Q24197474-16AFF25A-07FB-41B1-926C-8E92D4911B37Q27851658-C0703A7B-4121-41AE-AC22-F6A9DB949F1EQ30436395-49E0EF54-04EC-4DAC-8ED6-046B2B9E519EQ30436932-3C73F2A7-9A39-4090-BEDE-F6AECD845712Q33359764-4E0DCAEB-FD47-4798-AAA4-B5152458C093Q33407093-42195890-DB35-43F8-8922-1C397AFD2D77Q33560977-42E27BE6-1B99-4483-95B9-209E104D7C9BQ33623198-2E2AC1FB-7B80-4E67-9731-579B2CB108C6Q33648654-18DEEFC7-2678-4D85-8428-42403E83FD5DQ34089242-D24CEF5E-EDA0-4A1E-9F85-E24F3386DFFBQ34850394-DAA9DEBA-9D2C-4B98-BC92-3620E9CBE49BQ35625307-A2059586-EA81-4BE6-BB64-BA258B815E66Q36082772-898650C3-2D6C-4E33-BF9F-3DCDC2C6E9C2Q36241881-4F7C29A4-CA8C-46AF-8C3C-2C2550CA8596Q36946503-47481A34-5F5A-4735-8193-8002B2A464BDQ36977605-1DE124EF-9BBD-4A70-ACD9-EDF9AF97E9A7Q37139413-8DEC2476-45E4-404E-BA51-F996FCB454F2Q37316105-CFA56DD3-DF82-47F7-A800-B0DC1B181B5AQ37540968-AC32FCDE-618B-4400-9718-71C7452D3E25Q37843137-879C9237-D83C-46B9-973E-35D3BE6B58A2Q37943790-B8A998F1-B385-45D1-9C01-A8EC1B915AB4Q38089767-2D7BD586-9414-4D2A-9B5E-4E2D0783738EQ38395430-7792A970-FE43-4BA8-9F46-FC132BC678A8Q40038133-A1BEDA60-BD76-483D-96CE-2119D0C42157Q41296951-7C23CEBB-99AD-496D-A411-BE146F042D57Q41837402-B561A685-2D78-47FE-AB98-63ED7D628DD3Q42270985-24EC544F-E4E1-4BDA-9412-01377DE13421Q42744451-2191E84C-BE80-4560-B9B5-B6BF673C7B60Q46128098-57D73793-86FB-4EA2-B6E6-02AF50BE15B0Q47582021-0898268C-A0B3-42FE-8D21-DB2FDC48DF54Q54985726-9FD6DEB2-8C24-4437-9E55-2B24ED0F44ED
P2860
Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Epidermal growth factor recept ...... vix treated with radiotherapy.
@en
type
label
Epidermal growth factor recept ...... vix treated with radiotherapy.
@en
prefLabel
Epidermal growth factor recept ...... vix treated with radiotherapy.
@en
P2093
P1476
Epidermal growth factor recept ...... vix treated with radiotherapy.
@en
P2093
Alexander Tsodikov
David K Gaffney
Derek Haslam
Elizabeth Hammond
James Seaman
Joseph Holden
Karen Zempolich
Mark Dodson
R Jeffrey Lee
P304
P356
10.1016/S0360-3016(03)00209-8
P407
P577
2003-07-01T00:00:00Z